Clinical Operations: Biggest Challenges Facing the Industry in 2020

I’m often asked, by clients across the globe, what the main Clinical Operations challenges facing pharma and biotech companies really are. Where are they investing their resources? What takes up their time? Where are their efforts going to be focused...

5 years ago
Clinical Development,Clinical Operations,News

Clinical Operations: Biggest Challenges Facing the Industry in 2020

I’m often asked, by clients across the globe, what the main Clinical Operations challenges facing pharma and biotech companies really are. Where are they investing their resources? What takes up their time? Where are their efforts going to be focused...

5 years ago

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

5 years ago
Oncology,Bioprocess,Clinical Development,Weekly Roundups,Biology

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

5 years ago

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

5 years ago
Oncology,R&D,Biology,News

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

5 years ago

Weekly News Round-up – 7/2/20

Two big pharma restructures this week,with both GSK and Merck making promises to spin off or divide their existing assets. GSK disappointed some investors with its £2.4 billion plan to separate its consumer health arm and save £700 million a...

5 years ago
Bioprocess,Weekly Roundups

Weekly News Round-up – 7/2/20

Two big pharma restructures this week,with both GSK and Merck making promises to spin off or divide their existing assets. GSK disappointed some investors with its £2.4 billion plan to separate its consumer health arm and save £700 million a...

5 years ago

Trending Innovations in Cold Chain Processes

As is increasingly known in the pharmaceutical industry, the rise in both trial costs and drug failures has seen a corresponding increase in the need for tight regulations and stricter procedures, to ensure the few successes are not further compromised....

5 years ago
Bioprocess,Biomanufacturing,CMC,News

Trending Innovations in Cold Chain Processes

As is increasingly known in the pharmaceutical industry, the rise in both trial costs and drug failures has seen a corresponding increase in the need for tight regulations and stricter procedures, to ensure the few successes are not further compromised....

5 years ago

Weekly News Round-up – 31/1/20

With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...

5 years ago
R&D,Bioprocess,Weekly Roundups

Weekly News Round-up – 31/1/20

With the Chinese Coronavirus dominating the news this week, headlines were a diverse affair: Novartis has backed out of a generic program copying Advair, with the company citing that they could no longer see a way to launch in the...

5 years ago
Previous Page Showing 306 out of 322 Next Page
Working With us

Interested?
Reserve your space